Share This Article:

Prevalence of Wild-Type Butyrylcholinesterase Genotype in Patients with Alzheimer’s Dementia

Full-Text HTML XML Download Download as PDF (Size:224KB) PP. 175-179
DOI: 10.4236/wjns.2015.53019    2,575 Downloads   2,861 Views   Citations

ABSTRACT

Approximately, two-thirds patients with Alzheimer’s disease (AD) are reported to have homozygous wild-type butyrylcholinesterase (BuChE) gene expression. It is associated with a higher rate of hydrolysis of acetylcholine, which ultimately leads to increase in the levels of BuChE in advanced stages of the disease. Rivastigmine, a dual inhibitor of acetylcholinesterase (AChE) and BuChE, might be of additional benefit in patients with AD with wild-type BuChE allele.

Cite this paper

Mueller, B. and Adler, G. (2015) Prevalence of Wild-Type Butyrylcholinesterase Genotype in Patients with Alzheimer’s Dementia. World Journal of Neuroscience, 5, 175-179. doi: 10.4236/wjns.2015.53019.

References

[1] Noetzil, M. and Eap, C.B. (2013) Pharmacodynamic, Pharmacokinetic and Pharmacogenetic Aspects of Drugs Used in the Treatment of Alzheimer’s Disease. Clinical Pharmacokinetics, 52, 225-241.
http://dx.doi.org/10.1007/s40262-013-0038-9
[2] De-paula, V.J., Radanovic, N., Diniz, B.S. and Forlenza, O.V. (2012) Alzheimer’s Disease. Subcellular Biochemistry, 65, 329-352. http://dx.doi.org/10.1007/978-94-007-5416-4_14
[3] Schliebs, R. and Arendt, T. (2006) The Significance of the Cholinergic System in the Brain during Aging and in Alzheimer’s Disease. Journal of Neural Transmission, 113, 1625-1644.
http://dx.doi.org/10.1007/s00702-006-0579-2
[4] Francis, P.T. (2003) Glutamatergic Systems in Alzheimer’s Disease. International Journal of Geriatric Psychiatry, 18, S15-S21. http://dx.doi.org/10.1002/gps.934
[5] Anand, P. and Singh, B. (2013) A Review on Cholinesterase Inhibitors for Alzheimer’s Disease. Archives of Pharmacal Research, 36, 375-399. http://dx.doi.org/10.1007/s12272-013-0036-3
[6] Holmes, C., Ballard, C., Lehman, D., David Smith, A., Beaumont, H., Day, I.N., Nadeem Khan, M., Lovestone, S., McCulley, M., Morris, C.M., Munoz, D.G., O’Brien, K., Russ, C., Del Ser, T. and Warden, D. (2005) Rate of Progression of Cognitive Decline in Alzheimer’s Disease: Effect of Butyrylcholinesterase K Gene Variation. Journal of Neurology, Neurosurgery & Psychiatry, 76, 640-643. http://dx.doi.org/10.1136/jnnp.2004.039321
[7] Nordberg, A., Ballard, C., Bullock, R., Darreh-Shori, T. and Somogyi, M. (2013) Prim Care Companion CNS Disord. A Review of Butyrylycholinesterase as a Therapeutic Target in the Treatment of Alzheimer’s Disease, 15, 1-18.
[8] Chianella, C., Gragnaniello, D., Delser, P.M., Visentini, M.F., Sette, E., Tola, M.R., Barbujani, G. and Fuselliet, S. (2011) BCHE and CYP2D6 Genetic Variation in Alzheimer’s Disease Patients Treated with Cholinesterase Inhibitors. European Journal of Clinical Pharmacology, 67, 1147-1157.
http://dx.doi.org/10.1007/s00228-011-1064-x
[9] Bizzarro, A., Guglielmi, V., Lomastro, R., Valenza, A., Lauria, A., Marra, C., Silveri, M.C., Tiziano, F.D., Brahe, C. and Masullo, C. (2010) BuChE K Variant Is Decreased in Alzheimer’s Disease Not in Fronto-Temporal Dementia. Journal of Neural Transmission, 117, 377-383.
http://dx.doi.org/10.1007/s00702-009-0358-y
[10] Sodeyama, N., Yamada, M., Itoh, Y., Otomo, E., Suematsu, N. and Matsushita, M. (1999) Association between Butyrylcholinesterase K Variant and the Alzheimer Type Neuropathological Changes in Apolipoprotein E Epsilon4 Carriers Older than 75 Years. Journal of Neurology, Neurosurgery & Psychiatry, 67, 693-694. http://dx.doi.org/10.1136/jnnp.67.5.693
[11] Russ, C., Powell, J., Lovestone, S. and Holmes, C. (1998) K Variant of Butyrycholinesterase and Late-Onset Alzheimer’s Disease. The Lancet, 351, 881. http://dx.doi.org/10.1016/S0140-6736(05)70292-0
[12] Singleton, A.B., Smith, G., Gibson, A.M., Woodward, R., Perry, R.H., Ince, P.G., Edwardson, J.A. and Morris, C.M. (1998) No Association between the K Variant of the Butyrylcholinesterase Gene and Pathologically Confirmed Alzheimer’s Disease. Human Molecular Genetics, 7, 937-939.
http://dx.doi.org/10.1093/hmg/7.5.937
[13] Yamamoto, Y., Yasuda, M., Mori, E. and Maeda, K. (1999) Failure to Confirm a Synergistic Effect between the K-Variant of the Butyrylcholinesterase Gene and the Epsilon4 Allele of the Apolipoprotein Gene in Japanese Patients with Alzheimer’s Disease. Journal of Neurology, Neurosurgery & Psychiatry, 67, 94-96. http://dx.doi.org/10.1136/jnnp.67.1.94
[14] Kehoe, P.G., Williams, H., Holmans, P., Wilcock, G., Cairns, N.J., Neal, J. and Owen, M.J. (1998) The Butyrylcholinesterase K Variant and Susceptibility to Alzheimer’s Disease. Journal of Medical Genetics, 35, 1034-1035. http://dx.doi.org/10.1136/jmg.35.12.1034
[15] Grubber, J.M., Saunders, A.M., Crane-Gatherum, A.R., Scott, W.K., Martin, E.R., Haynes, C.S., Conneally, P.M., Small, G.W., Roses, A.D., Haines, J.L. and Pericak-Vance, M.A. (1999) Analysis of Association between Alzheimer’s Disease and the K Variant of Butyrylcholinesterase (BCHE-K). Neuroscience Letters, 269, 115-119. http://dx.doi.org/10.1016/S0304-3940(99)00426-7
[16] Lane, R., He, Y., Morris, C., Leverenz, J.B., Emre, M. and Ballard, C. (2009) BuChE-K and APOE ?4 Allele Frequencies in Lewy Body Dementias, and Influence of Genotype and Hyperhomocysteinemia on Cognitive Decline. Movement Disorders, 24, 392-400. http://dx.doi.org/10.1002/mds.22357
[17] Folstein, M.F. and Folstein, S.E. (1975) A Practical Method for Grading the Cognitive State of Patients for the Clinician. Journal of Psychiatric Research, 12, 189-198.
http://dx.doi.org/10.1016/0022-3956(75)90026-6
[18] Reisberg, B., Ferris, S.H, de Leon, M.J. and Crook, T. (1988) Global Deterioration Scale (GDS). Psychopharmacology Bulletin, 24, 661-663.
[19] Ferris, S., Nordberg, A., Soininen, H., Darreh-Shori, T. and Lane, R. (2009) Progression from Mild Cognitive Impairment to Alzheimer’s Disease: Effects of Sex, Butyrylcholinesterase Genotype, and Rivastigmine Treatment. Pharmacogenetics and Genomics, 19, 635-646.
http://dx.doi.org/10.1097/FPC.0b013e32832f8c17
[20] Bullock, R., Touchon, J., Bergman, H., Gambina, G., He, Y., Rapatz, G., Nagel, J. and Lane, R. (2005) Rivastigmine and Donepezil Treatment in Moderate to Moderately-Severe Alzheimer’s Disease over a 2-Year Period. Current Medical Research & Opinion, 21, 1317-1327.
http://dx.doi.org/10.1185/030079905X56565
[21] Blesa, R., Bullock, R., He, Y., Bergman, H., Gambina, G., Meyer, J., Rapatz, G., Nagel, J. and Lane, R. (2006) Effect of Butyrylcholinesterase Genotype on the Response to Rivastigmine or Donepezil in Younger Patients with Alzheimer’s Disease. Pharmacogenetics and Genomics, 16, 771-774.
http://dx.doi.org/10.1097/01.fpc.0000220573.05714.ac
[22] Massoud, F., Desmarais, J.E. and Guathier, S. (2010) Switching Cholinesterase Inhibitors in Older Adults with Dementia. International Psychogeriatrics, 23, 372-378.
http://dx.doi.org/10.1017/S1041610210001985

  
comments powered by Disqus

Copyright © 2017 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.